Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Operating Expenses (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Operating Expenses for 13 consecutive years, with $25.9 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 7.42% to $25.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $111.1 million through Dec 2025, changed 0.24% year-over-year, with the annual reading at $111.1 million for FY2025, 0.24% changed from the prior year.
  • Operating Expenses for Q4 2025 was $25.9 million at Theravance Biopharma, down from $26.4 million in the prior quarter.
  • The five-year high for Operating Expenses was $98.1 million in Q1 2021, with the low at $21.6 million in Q3 2022.
  • Average Operating Expenses over 5 years is $39.6 million, with a median of $29.8 million recorded in 2023.
  • The sharpest move saw Operating Expenses tumbled 67.68% in 2022, then rose 17.43% in 2024.
  • Over 5 years, Operating Expenses stood at $71.1 million in 2021, then plummeted by 54.89% to $32.1 million in 2022, then fell by 25.8% to $23.8 million in 2023, then grew by 17.43% to $28.0 million in 2024, then decreased by 7.42% to $25.9 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $25.9 million, $26.4 million, and $28.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.